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Antiviral treatment is an important tool in the clinical
management of severe or complicated influenza.
Two classes of antiviral agents for influenza are avail-
able: adamantanes (amantadine and rimantadine), and
neuraminidase inhibitors (oseltamivir, zanamivir, pera-
mivir, laninamivir). The currently circulating human
influenza viruses, influenza A (H1N1)pdm09, influenza
A(H3N2), and influenza type-B, are all resistant to ada-
mantanes, but most are sensitive to neuraminidase
inhibitors.
From April 2009 to 5 October 2011, a total of 605
cases of oseltamivir-resistant infections with influenza A
(H1N1) pdm09 virus have been reported to WHO from
32 countries. All resistant strains carry the H275Y sub-
stitution in the neuraminidase glycoprotein, which is
known to confer a high level of resistance to oseltamivir.
Of 468/605 (77%) cases with available clinical informa-
tion, 133/468 (28%) occurred among patients who were
severely immunocompromised. Of the patients who
were not immunocompromised, 211/335 cases (63%)
occurred after receiving treatment or prophylaxis with
antiviral drugs. Four clusters of oseltamivir-resistant
viruses with person-to-person transmission have been
reported: 2 occurred among severely immunocompro-
mised patients, while 2 were in healthy adults. Most
viruses carrying the H275Y substitution remain sensitive
to zanamivir. However reports indicate that other virus
variants have emerged resulting in a reduced sensitivity
to zanamivir and peramivir. Resistance to neuraminidase
inhibitors in influenza A (H3N2) and influenza type-B,
has been reported rarely, and has usually been asso-
ciated with prolonged treatment in immunocompro-
mised patients.
The prevalence of resistance to neuraminidase inhibi-
tors is still low, and oseltamivir remains the first line
treatment recommended for patients with severe influ-
enza or patients at a high risk of developing severe dis-
ease. However zanamivir is a therapeutic alternative for
patients infected with a virus that is highly suspected to
be resistant to oseltamivir, i.e., immunocompromised
patients who have received oseltamivir, but still have
evidence of persistent viral replication; or people who
develop illness despite taking oseltamivir for a post-
exposure prophylaxis. In addition appropriate infection
control measures should be implemented to prevent
spread of the resistant virus.
Although prevalence of resistance to neuraminidase
inhibitors remains low, reports of person-to-person
transmission, and an increased prevalence of resistant
viruses in community-based cases in specific regions,
emphase the necessity of virological and epidemiological
surveillance.
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